Pfizer plans to conduct offering of fixed-rate notes in five parts

By Devika Patel

Knoxville, Tenn., Nov. 14 – Pfizer Inc. intends to offer fixed-rate notes in five tranches, according to a 424B3 filing with the Securities and Exchange Commission.

The company will sell notes due 2019, 2021, 2026, 2036 and 2046.

The notes will have make-whole calls.

BofA Merrill Lynch, Citigroup Global Markets Inc. Credit Suisse Securities (USA) LLC and RBC Capital Markets Corp. are the bookrunners.

Proceeds will be used for a cash tender offer to purchase for cash any and all of the company’s $3.25 billion of 6.2% senior notes due March 15, 2019 and for general corporate purposes.

The biopharmaceutical company is based in Foster City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.